Published in Eur Radiol on October 06, 2006
Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol (2008) 2.23
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy (2012) 2.05
Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging (2013) 1.27
Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol (2009) 1.18
Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol (2013) 1.17
Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol (2013) 1.14
Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol (2012) 1.11
Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol (2008) 1.02
Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. World J Urol (2010) 0.98
Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol (2008) 0.96
New agents and techniques for imaging prostate cancer. J Nucl Med (2009) 0.96
MRI-targeted prostate biopsy: a review of technique and results. Nat Rev Urol (2013) 0.93
The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging. Eur Radiol (2008) 0.91
Performance comparison of 1.5-T endorectal coil MRI with 3.0-T nonendorectal coil MRI in patients with prostate cancer. Acad Radiol (2015) 0.91
Comparison of pelvic phased-array versus endorectal coil magnetic resonance imaging at 3 Tesla for local staging of prostate cancer. Yonsei Med J (2012) 0.89
Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol (2014) 0.87
Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol (2015) 0.87
Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J Endourol (2008) 0.85
Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer. Asian J Androl (2014) 0.85
Preoperative magnetic resonance imaging for detecting uni- and bilateral extraprostatic disease in patients with prostate cancer. World J Urol (2014) 0.83
Value of magnetic resonance imaging in prostate cancer diagnosis. World J Urol (2007) 0.81
Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy. J Contemp Brachytherapy (2014) 0.81
Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology. Eur Radiol (2014) 0.81
Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo. MAGMA (2008) 0.81
Modalities for imaging of prostate cancer. Adv Urol (2010) 0.80
Computer aided-diagnosis of prostate cancer on multiparametric MRI: a technical review of current research. Biomed Res Int (2014) 0.80
Accuracy of preoperative endo-rectal coil magnetic resonance imaging in detecting clinical under-staging of localized prostate cancer. World J Urol (2012) 0.80
Prostate MRI: access to and current practice of prostate MRI in the United States. J Am Coll Radiol (2014) 0.78
Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol (2014) 0.78
Poor standard mp-MRI and routine biopsy fail to precisely predict intraprostatic tumor localization. World J Urol (2016) 0.78
The role of imaging in the diagnosis of primary prostate cancer. J Clin Urol (2016) 0.77
Definitive 3D-CRT for clinically localized prostate cancer: modifications of the clinical target volume following a prostate MRI and the clinical benefits. Springerplus (2015) 0.77
Can high-spatial resolution T2-weighted endorectal MRI rule out clinically significant prostate cancer? World J Urol (2013) 0.76
Imaging and intervention in prostate cancer: Current perspectives and future trends. Indian J Radiol Imaging (2014) 0.76
Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance. Eur Radiol (2012) 0.76
Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter. World J Urol (2015) 0.76
Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study. J Med Imaging (Bellingham) (2016) 0.75
MRI in prostate cancer. Iran Red Crescent Med J (2013) 0.75
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
Basic principles of ROC analysis. Semin Nucl Med (1978) 27.12
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol (1996) 2.30
Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology (1995) 1.53
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol (2002) 1.50
Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol (1996) 1.46
Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology (1997) 1.43
Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. Radiology (1994) 1.33
Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol (1993) 1.33
Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology (1997) 1.32
The role of radical prostatectomy in the management of prostatic cancer. Cancer (1987) 1.32
Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology (2004) 1.21
Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology (1994) 1.20
Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology (1998) 1.13
Prostatic carcinoma: staging with MR imaging at 1.5 T. Radiology (1988) 1.07
Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology (2001) 1.05
Prostate cancer staging: should MR imaging be used?--A decision analytic approach. Radiology (2000) 1.05
Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology (1994) 1.02
Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int (2001) 0.99
Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol (1993) 0.99
MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy. Eur Radiol (1999) 0.92
MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. Radiology (1994) 0.91
Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology (2002) 0.91
The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol (1995) 0.90
MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. AJR Am J Roentgenol (1992) 0.89
Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur Radiol (1996) 0.88
Magnetic resonance imaging of prostate cancer: comparison of image quality using endorectal and pelvic phased array coils. Clin Radiol (1998) 0.84
Contrast-enhanced endorectal coil MRI in local staging of prostate carcinoma. J Comput Assist Tomogr (1995) 0.83
Fast spin-echo MR images of the pelvis obtained with a phased-array coil: value in localizing and staging prostatic carcinoma. AJR Am J Roentgenol (1993) 0.82
Clinical stage B prostate carcinoma: staging with MR imaging. Radiology (1987) 0.82
Invasion of the neurovascular bundle by prostate cancer: evaluation with MR imaging. Radiology (1991) 0.79
Detection of extracapsular extension of prostate cancer: role of fat suppression endorectal MRI. J Comput Assist Tomogr (1999) 0.79
Questions regarding the treatment of localized prostate cancer. Radiology (1992) 0.78
Carcinoma of the prostate: MR images obtained with body coils do not accurately reflect tumor volume. AJR Am J Roentgenol (1991) 0.78
Staging of prostatic cancer: accuracy of MR imaging. Radiology (1995) 0.78
Pelvic phased array coil: image quality assessment for spin-echo MR imaging. Magn Reson Imaging (1992) 0.76
Does microinvasion of the capsule and/or micrometastases in regional lymph nodes influence disease-free survival after radical prostatectomy? Br J Urol (1990) 0.76
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 8.78
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol (2009) 3.69
Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology (2014) 3.54
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch Intern Med (2010) 3.40
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology (2011) 2.92
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol (2004) 2.82
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol (2008) 2.77
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology (2003) 2.31
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology (2013) 2.19
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol (2006) 2.14
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
A case of abiraterone acetate withdrawal. Eur Urol (2013) 2.06
Imaging of urethral disease: a pictorial review. Radiographics (2004) 2.06
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol (2014) 1.77
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol (2011) 1.68
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol (2012) 1.66
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol (2010) 1.63
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years. J Pediatr Endocrinol Metab (2004) 1.59
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging (2012) 1.57
Dual-energy and low-kVp CT in the abdomen. AJR Am J Roentgenol (2009) 1.56
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol (2006) 1.56
Ultrasound detection of rotator cuff tears: observer agreement related to increasing experience. AJR Am J Roentgenol (2010) 1.54
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol (2009) 1.54
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol (2006) 1.51
Chronic perineal pain caused by pudendal nerve entrapment: anatomy and CT-guided perineural injection technique. AJR Am J Roentgenol (2003) 1.51
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol (2002) 1.50
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol (2007) 1.49
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis (2005) 1.49
Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol (2003) 1.48
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47
The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol (2006) 1.45
Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol (2010) 1.45
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int (2011) 1.44
Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol (2013) 1.44
Familial aggregation of urothelial cell carcinoma. Int J Cancer (2002) 1.43
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 1.43
Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int (2011) 1.42